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Abstract: Obesity is now a prevalent disease worldwide and has a multi-factorial etiology. Several
viruses or virus-like agents including members of adenoviridae, herpesviridae, slow virus (prion),
and hepatitides, have been associated with obesity; meanwhile obese patients are shown to be more
susceptible to viral infections such as during influenza and dengue epidemics. We examined the
co-factorial role of viral infections, particularly of the persistent cases, in synergy with high-fat diet in
induction of obesity. Antiviral interferons (IFNs), as key immune regulators against viral infections
and in autoimmunity, emerge to be a pivotal player in the regulation of adipogenesis. In this review,
we examine the recent evidence indicating that gut microbiota uphold intrinsic IFN signaling, which
is extensively involved in the regulation of lipid metabolism. However, the prolonged IFN responses
during persistent viral infections and obesogenesis comprise reciprocal causality between virus
susceptibility and obesity. Furthermore, some IFN subtypes have shown therapeutic potency in their
anti-inflammation and anti-obesity activity.
Keywords: persistent viral infection; interferon; lipid metabolism; obesity
1. Viral Infectobesity: The Association of Chronic Viral Infections with Obesity
According to recent statistics, the prevalence of obesity was 39.8% and affected about 93.3 million
US adults in 2015~2016 [1]. Similarly, in many other countries worldwide, overweight and obesity are
also dramatically on the rise, particularly in urban areas [2]. We face an obesity epidemic that has a
complex and multifactorial etiology [3]. While obesity is multifactorial, a simplified thermo-dynamic
model, rather than a biological model, has prevailed in obesity clinics for over 90 years [3]. A key
suggestion of this simplified model is to cut down one’s calorie intake and exercise more. While
addressing proximate causes of obesity serves as a global health priority, it seems incomplete or
ineffective to control obesity given that the epidemic has continued to worsen at the global level [1–3].
Recent investigations postulate that both physics and biology have tremendous utility for understanding
obesity. In this regard, we review the biological complex of obesity and interpret its etiology from the
interaction between immune and metabolic systems (i.e., immunometabolism). As pointed out by
Hotamisligil [4], metabolic and immune systems are among the most fundamental requirements and
are highly inter-dependent for species survival. Sequentially, obesity displays itself as a metabolic
overload (shown by excess adipose tissue) in addition to an immune disorder, which accompanies a
low-grade inflammatory state known as “meta-inflammation” involving both reprogrammed immune
cells and adipocytes [4]. Immunologically, chronic inflammation accompanies persistent infections
(either locally or systemically) as well as microbiota dysbiosis [5–12]. In addition, persistent infections
could also retain energy storage via adipogenesis at adipose depots for immune preparation [5,13,14].
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The visceral adipose depots in mammals, as counterparts of the insect fat body which functions as
both a storage and an immune organ, may evolutionarily enhance their role in anabolic storage for
combat readiness when facing long-term defense risks posed by pathogenic persistence [4,11–14]. In
this context, recent studies have associated obesity with numerous microbial agents in both humans
and animal models—a phenomenon described as infectobesity [15–17]. Microbial infections generally
beget inflammation and alter metabolic function in surrounding cells or even systemically in the animal
body. In this review, we recap the evidence of viral agents in association with obesity and relevant
metabolic syndrome [13–17]. In addition to examination of the major viruses or virus-like agents
(VLA) that have been associated with obesity, we emphasize shared immune responses underlying the
viral infectobesity. With this regard, interferons (IFNs), as a group of crucial cytokines in regulation of
antiviral and autoimmune processes, are key to understanding the pathogenesis of persistent viral
infections that are associated with most, if not all, viral infectobesity [11,12,18,19]. In addition, the effect
of IFNs and IFN-mediated signaling pathway (collectively known as the IFN system) in reprograming
cellular lipid metabolism provides a biochemical mechanism to understand the interaction of viral
infection and obesity [4,5,11,19].
As shown in Table 1, the major viruses and VLA that have been associated with obesity in both
humans and animal models include members of adenoviridae, herpesviridae, phages, transmissible
spongiform encephalopathies (slow virus), and hepatitides [15–17]. The additions to this list also include
Dengue fever virus (DENV) and HIV (which belong to Flavivirade and retroviridae, respectively) in
patients post the viral infections entering into a latent phase [20–24]. Voss and Dhurandhar (2017)
rationalized the biological plausibility of infectobesity caused by these viruses [15], which included:
(1) direct roles of some viruses to reprogram host metabolism toward a more lipogenic and adipogenic
status; (2) the probability that humans may exchange microbiota components (emphasizing its viral
component, i.e., virome/virobiota) from livestock reservoirs that have been aggressively selected for
efficient weight/fat gain; and (3) the adaptation of host immune and metabolic system under persistent
viral infections [15–18]. With regard to these, we emphasize the sequential immuno-metabolic adaption
to persistent viral infections, especially the subverted IFN response, which emerges as a key drive for
adipogenesis and obesity-associated immune suppression. This, in turn, underlies reciprocal causality
between obesity and higher susceptibility of obese individuals to viral infections [11–16].
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Table 1. Adipogenic viruses or virus-like agents and virus-interferon (IFN) interaction *.
Adipogenic Viruses *
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To recap the evidence of viral infectobesity, adenoviruses (Ad) including an avian isolate from
India (SMAM-1) and several serotypes of human Ad have been associated with obesity regarding
epidemiological correlation in certain subsets of humans and animals [15,24]. In addition, as SMAM-1
infection caused fat gain and high body mass index (BMI) in both birds and probably humans. At least
five human Ad serotypes including Ad-5, -9, 31, -36, and -37 have been observed to cause obesity at
different levels. First, these five Ad serotypes induced adipocyte differentiation and increased lipid
synthesis in cultured animal fibroblasts or pre-adipocytes. Second, Ad-5, Ad-37, and particularly Ad-36
infections increased the adipose index in animal models including chickens (Ad-36 and -37), mice (Ad-5
and -36), rats, and marmosets (Ad-36). Third, Ad-5 has been associated with child obesity and Ad-36
in both adults and children [15,24]. Mechanistically, Ad-36 infection activates peroxisome proliferator
activated receptor-γ (PPARγ) (which is the so-called master-switch of adipocyte development) to signal
adult stem cells to become adipocytes; meanwhile, the virus also induces the expression of some cell
glucose transporters to facilitate energy supply [25,26]. In addition, adenoviral E4orf1 protein (early
region 4 open reading frame 1) was identified as a viral mechanism mediating acute adipogenesis in cells
and animals [27,28]. Similarly, all other viruses and VLA listed in Table 1 have also been associated with
obesity in animals and humans through pathological studies or epidemiological observations; however,
other viral mechanisms (such as viral factors regulating inflammatory response and lipogenesis
in adipose depots) directly engaged in adipogenic effects warrant further investigation [15,29–45].
Notably, because phages do not directly infect animal cells, these bacterial viruses plausibly exert
an adipogenic effect by affecting the symbiosis of microbiota [31–34]. The adipogenic observation
in the patients of prion diseases (or coined as “slow viruses” previously), is plausibly ascribed to
host immuno-metabolic adaptation to the chronic pathogenesis during disease progress, because no
adipogenic effect has been associated to the prion protein [15,37–42]. In this context, we emphasize
that host immuno-metabolic adaptation to prolonged viral infection comprises a common etiology for
viral infectobesity. As multiple immune factors, particularly inflammatory cytokines (such as IL-1, IL-6,
and TNF-α) and adipokines (such as leptin and adiponectin), have been well-addressed elsewhere
in obesity, we highlight the regulatory role of the IFN system in immunometabolic regulation in the
scenario of viral infectobesity [4,11,12,30].
2. IFNs Emerging as a Key Factor to Mediate Viral Persistence and Relevant Infectobesity
Interferons (IFN) are vital antiviral cytokines evolved in vertebrates. Host cells secrete three
types of IFN peptides (i.e., type I, II and III IFNs) in response to viral infections. Three types of IFNs
not only differ in their molecular signatures and bind to distinct cell receptors, but also play distinct
tissue/cell-specific roles in control of viral infections. In brief, the innate immune IFNs, which include
multiple subtypes of type I and type III IFNs, provide early and local protection during viral entry
into animal portals. In contrast, IFN-γ, as the only member of type II IFN, is primarily produced by
specific immune cells (including natural killer cells (NK) and activated T cells) to mediate adaptive
immunity for eliminating dangerous pathogens that evade innate immunity [11,12,46–49]. Persistent
viral infections result from the virus escaping from immune clearance and entering into a co-existing
stage within the host cells to avoid excessive damage. The mechanisms to maintain persistent viral
infections are incompletely understood, but believably involve both modulation of viral actions and
reprograming of the host metabolic and immune responses [11,12,49]. Previous studies in mouse
models proposed that ineffective adaptive immune responses including lack of effective cytotoxic T
cells (CTL) and neutralizing antibodies are needed for viral persistence [11,12]. However, recent studies
indicate that innate immune IFNs are necessary in the regulation of viral infections during both early
and persistent phases [11,12,46–49]. Such as in mice infected by norovirus (MNV) and lymphocytic
choriomeningitis virus (LCMV), IFN-α/β played a systemic role in control of the viral replication and
clearance; and IFN-λs were effective in clearing enteric persistence of MNV [12,49,50]. Therefore, innate
immune IFNs preside over antiviral immunity to intervene chronic viral infection through mediating
at both innate (stimulation of expression of a plethora of ISG expression) and adaptive immune levels
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(exerting either positive or negative impacts on CTL and B-cell functions) [49–51]. Numerous studies
in HCV, HIV-1, and simian immunodeficiency virus (SIV) as well as multiple viruses in livestock
species place sustained type I IFN expression as a common nexus in the pathogenesis of multiple
chronic diseases [11,12,49]. Regarding viral pathogenesis, IFN responses during the acute phase of
viral infections is immuno-stimulatory and antiviral effective; however, the prolonged IFN production
(particularly of type I IFNs) in response to viral persistence is emerging as a double-edge sword actually
driving inflammation and immunosuppression [12,49–51]. In this context, examination of reported
studies about viral infectobesity indicates that most, if not all, of these obese situations correlate to the
chronic phases or persistent stages of viral infections (Table 1) [11–17]. In addition, the antagonism
to the host IFN system comprises a major mechanism of viruses that are capable of being persistent
or even harnessed as components of the host microbiota (virobiota) [52–62]. In other words, the
prolonged IFN response observed during most chronic viral pathogeneses may underlie, at least partly,
the immune dysfunction [11,12] that triggers metabolic disorders and obesity (Table 1) [4,13–17,63].
3. Gut Microbiota and Intrinsic Interferon Response
Current studies link gut microbiota to the development of obesity and its related comorbidities in
the following aspects [64–67]. First, changes of gut microflora affect adipogenesis or the pathogenesis of
obesity. It has been shown that healthy individuals have highly diverse gut microbiota than those with
obesity. The association of some bacterial taxonomic groups with obesity and relevant comorbidities
was observed such as lower content of Bacteroidetes in obese people and the association of Lactobacillus
and Clostridium with insulin resistance. These findings indicate that the disorder of gut microflora
could be a drive to obesity development. Second, germ-free (GF) animal models provide eloquent
evidence to address the role of gut microbiota in obesity induction. Without gut microbiota colonization,
GF mice were highly resistant to obesity induced by a high-fat diet than normal mice despite high
food intakes. Furthermore, GF mice that received fecal microbiota transplantation (FMT) from an
obese donor had higher weight gain than those receiving it from a lean donor. Misuses and overuses
of antibiotics in the animal industry and human medicine impact on gut microbial ecology, leading
to antibiotic resistance. Relevant studies using sub-therapeutic antibiotic treatment indicated that it
selectively eliminated vulnerable taxonomic groups of the gut microbiome, thus altering microbiome
composition that results in elevated hepatic metabolism of lipids and cholesterol in young mice [64–67].
Mechanistically, gut microbiota affect obesity development in an inter-systemic manner. Locally in the
gut, obesity-associated gut microbiota were selected for three properties: (1) a more efficient harvest
of energy from the diet; (2) gene reprogramming to facilitate energy anabolism; and (3) secretion of
bioactive molecules and hormones to affect host appetite. The decrease in gut microbiota diversity
in obese individuals impaired the intestinal barrier function and disturbed immune homeostasis by
inducing low-grade inflammation, which was considered an early trigger for adipogenesis [64,65].
Along with microbiome decomposition, the microbial shedding molecules such as liposaccharides
(LPS) induce further gut inflammation and immune-cell infiltration. Short-chain fatty acid (SCFAs)
released by microbiota directly fuel insulin-mediated lipogenesis and promote adipocyte differentiation.
Beyond the gut, the dysbiosis of gut microbiota also signals inflammation and hepatic T cell infiltration
to manifest as fatty liver frequently associated with obesity. Gut microbiota can also directly signal gut
afferent neurons and mediate the secretion of appetite hormones to regulate host metabolism through
the gut–brain axis and an endocrine pathway [66,67]. Therefore, collected evidence indicates that
local alteration in gut microbiota will lead to systemic reprograming in energy and lipid metabolism,
immune response, and endocrine functions that culminate in obesogenesis [64–67].
However, a majority of current studies about microbiota focus on cellular microbiome (including
bacteria, archaea, fungi, and protozoa), but overlook the viral community (i.e., virobiota or virome)
where it is at least ten-fold over more numerous than its cellular counterpart [68–71]. Indeed, a human
individual regardless of health status contains at least a dozen taxa of eukaryotic viruses and bacterial
phages. While phages potentially affect obesity indirectly through modulating bacterial composition,
Biomolecules 2019, 9, 726 6 of 17
eukaryotic viruses can directly interact with host cells to result in an ideal commensalism (symbiosis) or
cause either symptomatic or asymptomatic pathogenesis (dysbiosis). Compared with wild-type mice,
significantly higher viral contents were detected in the feces of obese mice. It was also indicated that
increased viral content, particularly viral RNA, was tightly correlated with an increase of fat mass and
potential hyperglycemia. Only total viral DNA/RNA mass was compared in this study, but the viral
taxonomic classification was not performed using metagenomic approaches [70]. However, their data
indicated that this obesity-correlated increase of viral content was mostly ascribed to phages [70]. This
reinforces the points from several recent reviews that the gut virome is a missing link underlying human
diseases like cancers and obesity [68,69,71]. Further studies are needed to decipher the composition of
gut commensal viruses and their role in obesogenesis through direct interaction on host cells [67–69].
Despite the lack of studies to correlate certain viral taxonomic groups with obesity in humans and
animals, they may have an overlapping spectrum with most persistent viruses associated with obesity
(Table 1) [13–17,68–71].
Evolutionarily, the IFN system represents a signature antiviral mechanism in high vertebrates.
The molecular evolution diversifies three types (type I, II, and III) and multiple subtypes/isoforms
within type I and type III IFNs. IFN-γ, as the single type II IFN, is mainly produced by NK cells
and CTLs and mediates pro-inflammatory response along with the activation of adaptive immune
cells. Type I IFNs such as IFN-α/β are expressed by most nucleated cells; in contrast, type III IFNs
are produced and active primarily in epithelial cells [11,18,46,51]. Even though type I and III IFNs
activate similar downstream signaling cascades in their responsive cells, respectively; type III IFNs
(IFNλs), unlike type I IFNs, do not elicit strong inflammatory responses in vivo [72]. The effects in
inflammatory induction of type I IFNs are more complicated. It depends on their subtypes, tissue
location, and even temporal phases during viral pathogenesis. For example, the universal IFN-α/β
subtypes may induce more pro-inflammatory response than IFN-κ or IFN-ε, which have a restrictive
expression in keratinocytes or the reproductive tract, respectively [51,71]. In addition, the sustained
IFN-α produced during persistent viral infections elicits more inflammatory cytokine responses [11,12].
Nevertheless, most of these antiviral IFN responses were observed during the infection of pathogenic
viruses. However, several recent studies discovered that, in addition to the robust IFN reaction to
infectious viruses, there is always an intrinsic IFN production signaled by gut microbiota [73–75]. In
homeostatic situations, gut epithelia and the underlying leukocytes (including NK cells, macrophages,
and dendritic cells) sense the natural shedding of microbial molecules from microbiota and sustain an
intrinsic expression of innate immune IFNs, particularly IFN-β and probably also the epithelial IFN-λ
subtype [72–75]. Acting through a non-canonical AKT-mTOR pathway (IFN-β) or an IRF1-indolent
process (IFN-λ), these intrinsic or local IFNs signal the expression of some anti-inflammatory and
cell growth cytokines including IL-10 and IL-13 to maintain an anti-inflammatory microenvironment,
which buffers a homeostatic resistance to meta-inflammation in obesity (Figure 1) [76–78]. Using
hydrodynamic gene transfer to increase peripheral IFN-β1 in mice fed a high-fat diet, a recent animal
trial showed that overexpression of Ifnb1 gene sequentially blocked adipose tissue expansion and
body weight gain, independent of food intake [79]. Although more investigations are needed, it is
logical to think that the gut virome, especially the “commensal” part should contribute to signaling the
intrinsic IFN-β response by microbiota. This thought is largely backed by the role of the gut virome
in modulating microbiome composition (such as by phages) as well as more sensitive IFN-inductive
effects from viral PAMPs compared to bacterial components [51,77].
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4. Regulation of Energy and Lipid Metabolism by Interferons
Instead of directly suppressing or killing viruses, IFNs restrict viruses through induction of
hundreds IFN-stimulated effector genes (ISGs) and alter cells to limit virus replication and spreading.
These cellular alterations include changes in protein synthesis, energy rebalance, lipid metabolism,
membrane composition, and cell proliferation [51,77]. We focused on their role in lipid metabolism to
highlight this functional aspect of IFNs because it is plausibly associated with adipogenesis and has
been overlooked by most studies of IFN biology in antiviral response [18,80–82].
Cell membranes provide a pivotal role and serve as a platform in viral life cycles from entry
and replication to assembly and exit. Indeed, the biochemical properties of cell membranes such as
fluidity, raft-domain structure, and lipid composition are among the major determinants affecting
different stages of viral infections [80–84]. In this context, both cholesterols and sphingolipids (including
ceramide) not only affect viral entry, replication, and exit for being structural components that determine
the biochemical property of cell membranes, but also actively serve as lipid signaling and direct
antiviral molecules to regulate both cellular antiviral responses as well as viral life cycles [83,84]. For
example, cholesterol is fundamental for most flavivirus infections in both mammal and insect cell
models [85], and 25-hydroxycholesterol (25HC) acts broadly to inhibit viral entry and replication [86].
Similarly, ceramide is an effective sphingosine-derived lipid that regulates diverse cellular immune
responses and was recently shown to directly inactivate influenza virus replication [87]. On the other
hand, viral infections also extensively modulate (and even actively hijack) cellular lipid metabolism to
benefit viral entry and replications. The readers may refer to several recent reviews for details on this
topic [83–85].
In Figure 2, we illustrate the major effect of type I IFNs in the regulation of cellular energy and lipid
metabolism from recent and early studies [88–105]. For energy metabolism, type I IFNs enhance glucose
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uptake in both mouse embryonic fibroblasts and human plasmacytoid dendritic cells (pDCs) [18,88–91].
Similarly, IFN-induced increases of glycolysis, oxidative phosphorylation, and ATP production derived
from the TCA cycle have been observed in multiple human cells including macrophages, DCs, T cells,
keratinocytes, and some cancer cell lines [18,80,81,91–94]. Particularly in macrophages, IFNs also act on
the cellular TCA cycle to stimulate the synthesis of reactive oxygen species (ROS) and itaconic acid to
augment the cell antimicrobial activity against engulfed pathogens [82,89,95–98]. The IFN suppression
of lipid metabolism is multifaceted, and can occur by directly repressing the synthesis of fatty acid (FA)
and cholesterol in HeLa cells, and by regulating the upstream mediators of AMPK and mTOR complex
in several human and mouse cells [99–104]. Similarly, in livestock cells, we determined that IFNs exert
potent antiviral and immunomodulatory activities through interaction with the metabolic system [76].
The expression of IFNs is regulated either by the nutrient sensor mTOR, or by direct reprograming of
the lipid metabolic pathways. Thus, a mutual relationship between IFN production and metabolic
core processes is manifested in antiviral responses [4,76,99–103]. For example, type I IFNs induce the
synthesis of 25-hydroxycholesterol (25HC), a potent metabolite in cholesterol metabolism that exerts
a broad antiviral activity and suppressive effect in production of inflammatory cytokines including
IL-1 and TNF-α [82,86,96]. In addition, type I IFNs also promote the cross-membrane import of
cholesterol and FA into the cells and strengthen membrane rigidity in multiple human cells [80,81].
Potentially, lipogenesis is a sub-effect of the IFN antiviral activity via increase of 25HC synthesis and
cholesterol/FA import, particularly under a situation of persistent viral infections. Plasma ceramide and
dihydroceramide levels are a biomarker of insulin resistance and obesity, and molecular manipulation
of body ceramide to control obesity was illuminated by a recent elegant study [104]. Notably, other
reports indicated that both IFN-γ and IFN-β are potent to regulate ceramide metabolism [104,105].
Taken together, the effective IFN response during acute phases of antiviral responses may actually
suppress meta-inflammation and reduce energy flow toward lipogenesis in adipocytes. However, the
prolonged IFN responses during chronic viral infections might be an adipogenic drive and could lead
to immune suppression mostly in obesity patients (see Figure 3 and the next section) [80,81].Bio olecules 2019, 8, x FOR PEER REVIEW 10 of 19 
 
 
Figure 2. Antiviral IFN stimulation and the effect on energy and lipid metabolism. Counteracting 
viral infections, which seize the cell energy and lipid metabolism for viral production but enhance 
fatty acid (FA) and cholesterol synthesis, effective IFN response leads to an antiviral state through an 
IFN autocrine or paracrine regulatory loop. The induction of antiviral state is accompanied by a 
general arrest of protein and lipid metabolism. The IFN suppression of lipid metabolism is 
multifaceted such as directly repressing the synthesis of FA and cholesterol, and regulating via the 
upstream regulators of AMPK and mTOR complex. In addition, IFNs have been also implicated in 
the regulation of glycolysis, TCA cycle, and cholesterol transport to facilitate cell antiviral response. 
Taking together, the effective IFN response, especially that during acute phases of antiviral responses, 
is unlikely to induce obesity and meta-inflammation underlying obesity; however, the prolonged IFN 
responses during chronic viral infections might be an adipogenic drive in an opposite way (Figure 3). 
Abbreviations: acetyl-CoA, acetyl coenzyme A; Akt/PI3K/mTOR, phosphatidylinositol-3-kinase 
(PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathway; AMPK, 5-adenosine 
monophosphate-activated protein kinase; FA, fatty acid; FAO, fatty acid oxidation; IFN-I, type I 
interferon; 25HC, 25-hydroxycholesterol; ROS, reactive oxygen species; SREBP, sterol regulatory 
binding protein; TCA cycle, tricarboxylic acid cycle. Adapted from [80,81] with a permission. 
viruses are associated with obesity, we propose an immuno-pathological explanation about 
pathogenic persistence and subverted immune deviation (such as prolonged IFN-α response irritated 
during chronic viral infections) is a theme underlying viral infectobesity [11,12,16,19]. As depicted in 
Figure 1, the intrinsic gut IFN-β response and early mucosal IFN-λ response to acute viral infections 
generally promote less inflammation and cause negligible tissue damage [72–75]. However, the later 
and particularly prolonged type I IFN response during the viral persistence entails a systemic 
inflammatory response in terms of the induction of pro-inflammatory cytokines (including IL-1, IL-
6, and IL-18 in myeloid cells and TNF-α from monocytic cells) and activation of inflammatory 
lineages of macrophages, NK cells, and hepatic T cells [11,12,106,107]. Systemic and adipose tissue-
specific meta-inflammation, manifested by these inflammatory cytokines and immune cells, are 
exaggerated by the immune responses induced by both viral persistence and some obesogens, which 
sustain obesogenesis and complicate into infectobesity [4,7,64,66].  
Figure 2. Antiviral IFN stimulation and the eff ct on e ergy and lipid metabolism. Counteracting viral
infections, which seize the cell energy a d lipid metabolism for viral production but enhance fatty acid
Biomolecules 2019, 9, 726 9 of 17
(FA) and cholesterol synthesis, effective IFN response leads to an antiviral state through an IFN
autocrine or paracrine regulatory loop. The induction of antiviral state is accompanied by a general
arrest of protein and lipid metabolism. The IFN suppression of lipid metabolism is multifaceted such
as directly repressing the synthesis of FA and cholesterol, and regulating via the upstream regulators of
AMPK and mTOR complex. In addition, IFNs have been also implicated in the regulation of glycolysis,
TCA cycle, and cholesterol transport to facilitate cell antiviral response. Taking together, the effective
IFN response, especially that during acute phases of antiviral responses, is unlikely to induce obesity
and meta-inflammation underlying obesity; however, the prolonged IFN responses during chronic
viral infections might be an adipogenic drive in an opposite way (Figure 3). Abbreviations: acetyl-CoA,
acetyl coenzyme A; Akt/PI3K/mTOR, phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian
target of rapamycin (mTOR) signaling pathway; AMPK, 5-adenosine monophosphate-activated protein
kinase; FA, fatty acid; FAO, fatty acid oxidation; IFN-I, type I interferon; 25HC, 25-hydroxycholesterol;
ROS, reactive oxygen species; SREBP, sterol regulatory binding protein; TCA cycle, tricarboxylic acid
cycle. Adapted from [80,81] with a permission.
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Figure 3. A reciprocal causality of obesity and chronic viral infections. High-fat diet and viral infection
(particularly chronic viral infections) may independently (or synergistically in most time) induce
dysbiosis of gut microbiota leading to gut inflammation and leaking, which at least partly results
from prolonged IFN production upon chronic viral infection and underlies systemic inflammation
of obesity. In turn, through the production of long-chain fatty acid (LFA) and leptin by expanding
adipocytes, obesity is accompanied with meta-inflammation (enhanced by LFA) and susceptibility to
viral infections (through suppression of IFN antiviral signaling by leptin induction of SOCS3 signaling).
Abbreviations: NF-κB, nuclear factor-kappa B; P-STAT, phosphorylated signal transducer and activator
of transcription; RIG-I, retinoic acid-inducible gene I; SOCS3, suppressor of cytokine signaling 3; TNF,
tumor necrosis factor; and that in the legend of Figure 1.
5. Interferon Responses Underlying the Reciprocal Causality of Obesity and Persistent
Viral I fections
The association of obesity with various viral infections has always faced a “chicken or egg”
disputation [13–17]. Do viral infections trigger the infectobesity first, or does obesity lead to higher
susceptibility to viral infections that manifest the comorbidity? As described above, we reinforced the
reciprocal causality of viral infections and obesity underlying the infectobesity [14]. First, multiple
viruses and VLAs have been epidemiologically associated with obesity and some with identified
mechanisms in adipogenic or lipogenic induction (Table 1) [13–17]. As more infectious agents beyond
viruses are associated with obesity, we propose an immuno-pathological explanation about pathogenic
persistence and subverted immune deviation (such as prolonged IFN-α response irritated during
chronic viral infections) is a theme underlying viral infectobesity [11,12,16,19]. As depicted in Figure 1,
the intrinsic gut IFN-β response and early mucosal IFN-λ response to acute viral infections generally
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promote less inflammation and cause negligible tissue damage [72–75]. However, the later and
particularly prolonged type I IFN response during the viral persistence entails a systemic inflammatory
response in terms of the induction of pro-inflammatory cytokines (including IL-1, IL-6, and IL-18 in
myeloid cells and TNF-α from monocytic cells) and activation of inflammatory lineages of macrophages,
NK cells, and hepatic T cells [11,12,106,107]. Systemic and adipose tissue-specific meta-inflammation,
manifested by these inflammatory cytokines and immune cells, are exaggerated by the immune
responses induced by both viral persistence and some obesogens, which sustain obesogenesis and
complicate into infectobesity [4,7,64,66].
On the other hand, obesity also provokes an aberration in the immune system including the
attenuated and prolonged type I IFN response that shows antiviral inefficacy. Obese individuals have
a high level of blood leptin, implying a situation of “leptin resistance”. Leptin potentially upregulates
the suppressor of cytokine signaling-3 (SOCS-3). SOCS3 upregulation and altered systemic leptin
levels could be responsible for the reduced type I IFN response as well as other immune dysfunction
relevant to T cells and B cells in people with obesity [4,14,19,77,106]. IFN signaling occurs via the same
JAK–STAT pathway and is negatively regulated by SOCS-3, suggesting a potential mechanism by which
IFN responses to viral infections may be suppressed in obese individuals [14,48]. Teran-Cabanillas
et al. (2017) have recently evaluated the effect of SOCS expression and type I IFN responses in
obese patients, showing that basal SOCS-3 expression was increased in obesity and correlated to
the reduction of type I IFN and pro-inflammatory cytokine responses [48]. This obesity-associated
immune dysfunction, particularly attenuated IFN responses, resulted in potential increase of host
susceptibility to viral infections; therefore leading to increased prognoses of associated viruses from
secondary infections, co-infections, and even opportunistic infections in obese patients. A collection
of data from clinical cases in humans and studies in mouse models showed that obese individuals
exhibited higher susceptibility and mortality during seasonal and epidemic flu infections [5,108]. More
severe lung inflammation and lung damage from viral pneumonia as well as prolonged viral shedding
were observed in both obese mice and human cases. It was schematically summarized that multiple
immune responses including IFN-α/β production and IFN-signaling of ISG production were impaired
in the respiratory epithelial cells and macrophages of obese individuals, along with the increase of
inflammatory cytokines and M1 polarization of lung macrophages [5,108]. Therefore, the deficiency of
IFN production and signaling in obese patients might be among the risk factors for severe outcomes
in pandemic influenza infection [5,14,108]. In one report, the incidence of DENV infections seemed
higher in obese patients, but needed more epidemiological evidence to justify [20,21]. In the cases
of HIV and HCV infections, the persistence of viral infections in obese patients was complicated by
accompanied ART or IFN therapies, respectively [22,23,43–45,60]; however, evidence from another
side suggests that persistent viral infection and perturbation of IFN signaling exacerbate obesity
development. Regarding systemic interaction in animal and human bodies, high-fat diet and viral
infection (particularly chronic viral infections) may synergistically (or independently sometime) induce
dysbiosis of gut microbiota and systemic low-grade inflammation. These systemic changes partially
result from attenuated and prolonged IFN production upon persistent viral infections and underlie
the systemic inflammation observed in obesity [4,11–17]. A recent study by Ghazarian et al. (2017)
showed that type I IFN–driven activation of CD8+ T cells in the liver correlates with insulin resistance
in obesity-linked fat liver (termed nonalcoholic fatty liver disease, NAFLD) in obese patients [107].
This study also critically associated gut microbiome with liver IFN signaling and its role in driving
inflammation in the livers of obese mice [107]. It is likely that the dysbiotic microbiome in the obesity
and NAFLD patients may harbor persistent infections. In turn, through over-production of long-chain
fatty acid (LFA) and leptin by expanding adipocytes, obesity is accompanied with general immune
suppression including aberration of antiviral IFN signaling, which leads to high susceptibility to
viral infections (Figure 3) [4,11,48,107,109]. Therefore, in most cases of infectobesity, obesity and
viral infections may interact dynamically as a reciprocal causality rather than a simple sequential
relationship of “chicken or the egg” [14]. Moreover, IFN (particularly type I IFNs) responses have
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recently been postulated as a central immunological axis that governs adipocyte differentiation and
T cell pathogenicity during obesity-associated metabolic disease [107–109]. All these observations
collectively indicate that IFNs may directly reprogram cellular lipid synthesis and transport, in addition
to its indirect effect through interaction with viral infections.
6. Prospects of Interferon-Based Anti-Obesity Therapies
The emerging theme of IFNs as a critical regulator of obesity has been demonstrated by several
reports targeting therapeutic development against obesity in both cell and animal models. McGillicuddy
et al. (2009) reported that IFN-γ treatment reduced insulin-stimulated glucose uptake in human
adipocytes, attenuated insulin sensitivity, and suppressed differentiation of pre-adipocytes to the
mature phenotype. The anti-adipogenic effect of IFN-γ is most likely mediated via sustained JAK-STAT1
pathway activation [110]. Using a mouse model, another study detected the stimulation of type I
IFN responses by long chain FA in murine hepatocytes and macrophages. Targeting abrogation of
IFN-signaling in adipose tissue, but not hepatocyte-specific deletion of Ifnar1 worsened HFD-induced
metabolic syndrome. Conversely, improved metabolic control in laparoscopic adjustable gastric
banding patients with obesity was associated with stimulation of type I IFN-regulated genes in
subcutaneous adipose tissue and liver [111]. This study indicated the differential role of IFN-signaling
through the regulation of different sets of ISGs (such as IRFs, IFITs, MX1, and OAS1) in different
cells (particularly adipocytes/hepatocytes) that are closely relevant to the development of obesity
and metabolic disorders [111]. Again, using hydrodynamic gene transfer to elevate and sustain
blood concentration of IFN-β1 in mice suppressed immune cell infiltration and production of
pro-inflammatory cytokines, and blocked adipose tissue expansion and body weight gain, independent
of food intake [79]. However, such expression may boost a super-physiological and potentially
persistent level of IFN-β in the liver. Yet, persistent IFN-β signaling could induce partially immune
exhaustion both centrally and locally and would require further study for pharmaceutic safety.
Metabolically, IFN-β1, as an intrinsic responder to gut interaction with its microflora (including
virome), has been experimentally shown to improve insulin sensitivity and glucose homeostasis in
obese mice [46,79]. These findings, even though preliminary, suggest that targeting IFN signaling
represents a promising strategy to block obesity development and its related pathologies. So, how about
other IFN subtypes besides type II IFN-γ and type I IFN-β? Ying et al. (2014) administered IFN-τ, a
ruminant IFN subtype acting as a signaling molecule during pregnancy in trophoblasts, into obese mice
induced by HFD [112]. They showed that this livestock IFN subtype not only significantly mitigated
obesity-associated systemic insulin resistance and adipose inflammation by controlling macrophage
polarization, but also had less cytotoxic effect than typical IFN-β subtype, indicating a therapeutic
potential through cross-species screening of IFN molecules [46,79,111,112]. We know that type I IFNs
are eminent for their unconventional subtypes, which are functionally prone to anti-inflammatory and
reproductive regulation in livestock species such as pigs and cattle as well as type III IFNs that are
restricted to epithelial expression [46]. Information from the study of tissue-specific IFN-signaling
effect by Wiser et al. (2018) implies that epithelial IFN-signaling has limited regulation on metabolic
and hepatic diseases [111]. Based on these insightful studies for IFN-based anti-obesity therapies,
a cross-species and family-wide screening of the most effective IFN ligands is needed, and may
provide more IFN-based options for therapeutic optimization against current obesity prevalence and
reveal IFN subtypes that bear superior activity in anti-obesity or metabolic regulation to IFN-β or
IFN-γ [46,79,110–112].
7. Conclusive Remarks
Interferons, as a family of key cytokines, exert broad antiviral, anti-tumor, and anti-proliferative
activities in vitro and in vivo [11,18,46,51]. The broad activity of IFNs depends on inducing hundreds
of ISGs, which not only directly restrict virus infections at different stages of viral life cycle, but
also orchestrate cell metabolism to enter into an antiviral state [11,51]. In this manner, IFNs have
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been found to play a role in reprogramming cell lipid metabolism in addition to their activity in
coordinating RNA and protein metabolism [80,81,88]. This underpins a metabolic basis of IFNs
in the development of obesity, and particularly, the infectobesity involving viral infections [13–17].
Effective IFN responses, especially those mediated by type I and type III IFNs, are postulated to be
an immunological axis that determines antiviral defense. However, the futile and prolonged IFN
response accompanying persistent viral infections actually compromise body function in both antiviral
immunity and metabolic normality [11,12]. On the other hand, the cross-talking of leptin and LFA with
IFN signaling provides another rationale to associate IFNs with obesity [29,48]. However, more direct
evidence such as using IFN-signaling deficient animal models are needed to conclusively determine if
and how fundamental IFN signaling plays a role in obesity development. Remarkably, all immune
responses are a double-edged sword, as it is for IFN-signaling [11,12,19,50,51]. Although the intrinsic
and properly stimulated IFN responses are favorable for antiviral and anti-obesity effect; on the other
hand, there are multiple literatures also suggesting that improper IFN responses may actually impair
viral clearance, and promote hepatic and metabolic diseases [19,50,51,107]. Thus, for the development
of IFN-based therapeutics for anti-obesity purposes, effective IFN regimens need to be selected and
tested dynamically to overcome potential side-effects such as those manifested from antiviral IFN
therapeutics [113].
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6. Preveden, T.; Scarpellini, E.; Milić, N.; Luzza, F.; Abenavoli, L. Gut microbiota changes and chronic hepatitis
C virus infection. Expert Rev. Gastroenterol. Hepatol. 2017, 11, 813–819. [CrossRef] [PubMed]
7. Man, S.M. Inflammasomes in the gastrointestinal tract: Infection, cancer and gut microbiota homeostasis.
Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 721–737. [CrossRef] [PubMed]
8. Debédat, J.; Clément, K.; Aron-Wisnewsky, J. Gut Microbiota dysbiosis in human obesity: Impact of bariatric
surgery. Curr. Obes. Rep. 2019, 8, 229–242. [CrossRef] [PubMed]
9. Toor, D.; Wsson, M.K.; Kumar, P.; Karthikeyan, G.; Kaushik, N.K.; Goel, C.; Singh, S.; Kumar, A.; Prakash, H.
Dysbiosis disrupts gut immune homeostasis and promotes gastric diseases. Int. J. Mol. Sci. 2019, 20, E2432.
[CrossRef] [PubMed]
10. Uchiyama, K.; Naito, Y.; Takagi, T. Intestinal microbiome as a novel therapeutic target for local and systemic
inflammation. Pharm. Ther. 2019, 199, 164–172. [CrossRef] [PubMed]
11. Snell, L.M.; McGaha, T.L.; Brooks, D.G. Type I interferon in chronic virus infection and cancer. Trends Immunol.
2017, 38, 542–557. [CrossRef] [PubMed]
12. Dagenais-Lussier, X.; Loucif, H.; Murira, A.; Laulhé, X.; Stäger, S.; Lamarre, A.; van Grevenynghe, J. Sustained
IFN-I expression during established persistent viral infection: A “bad seed” for protective immunity. Viruses
2017, 10, E12. [CrossRef] [PubMed]
Biomolecules 2019, 9, 726 13 of 17
13. Sohrab, S.S.; Kamal, M.A.; Atkinson, R.L.; Alawi, M.M.; Azhar, E.I. Viral infection and obesity: Current
status and future prospective. Curr. Drug Metab. 2017, 18, 798–807. [CrossRef] [PubMed]
14. Hainer, V.; Zamrazilová, H.; Kunešová, M.; Bendlová, B.; Aldhoon-Hainerová, I. Obesity and infection:
Reciprocal causality. Physiol. Res. 2015, 64 (Suppl. 2), S105–S119.
15. Voss, J.D.; Dhurandhar, N.V. Viral infections and obesity. Curr. Obes. Rep. 2017, 6, 28–37. [CrossRef]
[PubMed]
16. Pasarica, M.; Dhurandhar, N.V. Infectobesity: Obesity of infectious origin. Adv. Food Nutr. Res. 2007, 52,
61–102. [PubMed]
17. Voss, J.D.; Leon, J.C.; Dhurandhar, N.V.; Robb, F.T. Pawnobiome: Manipulation of the hologenome within
one host generation and beyond. Front. Microbiol. 2015, 6, 697. [CrossRef] [PubMed]
18. Wu, D.; Sanin, D.E.; Everts, B.; Chen, Q.; Qiu, J.; Buck, M.D.; Patterson, A.; Smith, A.M.; Chang, C.H.; Liu, Z.;
et al. Type 1 Interferons induce changes in core metabolism that are critical for immune function. Immunity
2016, 44, 1325–1336. [CrossRef] [PubMed]
19. Nice, T.J.; Osborne, L.C.; Tomov, V.T.; Artis, D.; Wherry, E.J.; Virgin, H.W. Type I interferon receptor deficiency
in dendritic cells facilitates systemic murine norovirus persistence despite enhanced adaptive immunity.
PLoS Pathog. 2016, 12, e1005684. [CrossRef] [PubMed]
20. Tan, V.P.K.; Ngim, C.F.; Lee, E.Z.; Ramadas, A.; Pong, L.Y.; Ng, J.I.; Hassan, S.S.; Ng, X.Y.; Dhanoa, A. The
association between obesity and dengue virus (DENV) infection in hospitalised patients. PLoS ONE 2018, 13,
e0200698. [CrossRef] [PubMed]
21. Badawi, A.; Velummailum, R.; Ryoo, S.G.; Senthinathan, A.; Yaghoubi, S.; Vasileva, D.; Ostermeier, E.;
Plishka, M.; Soosaipillai, M.; Arora, P. Prevalence of chronic comorbidities in dengue fever and West Nile
virus: A systematic review and meta-analysis. PLoS ONE 2018, 13, e0200200. [CrossRef] [PubMed]
22. Lake, J.E. The fat of the matter: Obesity and visceral adiposity in treated HIV infection. Curr. HIV/AIDS Rep.
2017, 14, 211–219. [CrossRef] [PubMed]
23. Lake, J.E.; Stanley, T.L.; Apovian, C.M.; Bhasin, S.; Brown, T.T.; Capeau, J.; Currier, J.S.; Dube, M.P.; Falutz, J.;
Grinspoon, S.K.; et al. Practical review of recognition and management of obesity and lipohypertrophy in
human immunodeficiency virus infection. Clin. Infect. Dis. 2017, 64, 1422–1429. [CrossRef] [PubMed]
24. Voss, J.D.; Atkinson, R.L.; Dhurandhar, N.V. Role of adenoviruses in obesity. Rev. Med. Virol. 2015, 25,
379–387. [CrossRef] [PubMed]
25. Floyd, Z.E.; Stephens, J.M. Controlling a master switch of adipocyte development and insulin sensitivity:
Covalent modifications of PPARγ. Biochim. Biophys. Acta 2012, 1822, 1090–1095. [CrossRef] [PubMed]
26. Dubuisson, O.; Dhurandhar, E.J.; Krishnapuram, R.; Kirk-Ballard, H.; Gupta, A.K.; Hegde, V.; Floyd, E.;
Gimble, J.M.; Dhurandhar, N.V. PPARgamma-independent increase in glucose uptake and adiponectin
abundance in fat cells. Endocrinology 2011, 152, 3648–3660. [CrossRef] [PubMed]
27. Dhurandhar, E.J.; Dubuisson, O.; Mashtalir, N.; Krishnapuram, R.; Hegde, V.; Dhurandhar, N.V. E4orf1: A
novel ligand that improves glucose disposal in cell culture. PLoS ONE 2011, 6, e23394. [CrossRef] [PubMed]
28. Dhurandhar, N.V. Insulin sparing action of adenovirus 36 and its E4orf1 protein. J. Diabetes Complicat. 2013,
27, 191–199. [CrossRef] [PubMed]
29. Vangipuram, S.D.; Yu, M.; Tian, J.; Stanhope, K.L.; Pasarica, M.; Havel, P.J.; Heydari, A.R.; Dhurandhar, N.V.
Adipogenic human adenovirus-36 reduces leptin expression and secretion and increases glucose uptake by
fat cells. Int. J. Obes. 2007, 31, 87–96. [CrossRef] [PubMed]
30. Sanchez, E.L.; Lagunoff, M. Viral activation of cellular metabolism. Virology 2015, 479–480, 609–618. [CrossRef]
[PubMed]
31. Ridaura, V.K.; Faith, J.J.; Rey, F.E.; Cheng, J.; Duncan, A.E.; Kau, A.L.; Griffin, N.W.; Lombard, V.; Henrissat, B.;
Bain, J.R.; et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013,
341, 1251214. [CrossRef] [PubMed]
32. Mills, S.; Shanahan, F.; Stanton, C.; Hill, C.; Coffey, A.; Ross, R.P. Movers and shakers: Influence of
bacteriophages in shaping the mammalian gut microbiota. Gut Microbes. 2013, 4, 4–16. [CrossRef] [PubMed]
33. Bahra, S.M.; Weidemann, B.J.; Castro, A.N.; Walsh, J.W.; deLeon, O.; Burnett, C.M.; Pearson, N.A.; Murry, D.J.;
Grobe, J.L.; Kirby, J.R. Risperidone-induced weight gain is mediated through shifts in the gut microbiome
and suppression of energy expenditure. EBioMedicine 2015, 2, 1725–1734. [CrossRef] [PubMed]
Biomolecules 2019, 9, 726 14 of 17
34. Gogokhia, L.; Buhrke, K.; Bell, R.; Hoffman, B.; Brown, D.G.; Hanke-Gogokhia, C.; Ajami, N.J.; Wong, M.C.;
Ghazaryan, A.; Valentine, J.F.; et al. Expansion of bacteriophages is linked to aggravated intestinal
inflammation and colitis. Cell Host Microbe 2019, 25, 285–299. [CrossRef] [PubMed]
35. Cheng, J.; Ke, Q.; Jin, Z.; Wang, H.; Kocher, O.; Morgan, J.P.; Zhang, J.; Crumpacker, C.S. Cytomegalovirus
infection causes an increase of arterial blood pressure. PLoS Pathog. 2009, 5, e1000427. [CrossRef] [PubMed]
36. Hamer, M.; Batty, G.D.; Kivimäki, M. Obesity, metabolic health, and history of cytomegalovirus infection in
the general population. J. Clin. Endocrinol. Metab. 2016, 101, 1680–1685. [CrossRef] [PubMed]
37. Liberski, P.P.; Gajos, A.; Sikorska, B.; Lindenbaum, S. Kuru, the first human prion disease. Viruses 2019, 11,
E232. [CrossRef] [PubMed]
38. Kim, Y.S.; Carp, R.I.; Callahan, S.M.; Wisniewski, H.M. Scrapie induced obesity in mice. J. Infect. Dis. 1987,
156, 402–405. [CrossRef] [PubMed]
39. Carp, R.I.; Callahan, S.M.; Sersen, E.A.; Moretz, R.C. Preclinical changes in weight of scrapie-infected mice as
a function of scrapie agent-mouse strain combination. Intervirology 1984, 21, 61–69. [CrossRef] [PubMed]
40. Kim, Y.S.; Carp, R.I.; Callahan, S.M.; Wisniewski, H.M. Adrenal involvement in scrapie-induced obesity. Proc.
Soc. Exp. Biol. Med. 1988, 189, 21–27. [CrossRef] [PubMed]
41. Strom, A.; Yutzy, B.; Kruip, C.; Ooms, M.; Schloot, N.C.; Roden, M.; Scott, F.W.; Loewer, J.; Holznagel, E.
Foodborne transmission of bovine spongiform encephalopathy to non-human primates results in preclinical
rapid-onset obesity. PLoS ONE 2014, 9, e104343. [CrossRef] [PubMed]
42. de Brito, G.; Lupinacci, F.C.; Beraldo, F.H.; Santos, T.G.; Roffé, M.; Lopes, M.H.; de Lima, V.C.; Martins, V.R.;
Hajj, G.N. Loss of prion protein is associated with the development of insulin resistance and obesity. Biochem.
J. 2017, 474, 2981–2991. [CrossRef] [PubMed]
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